Anebulo Pharmaceuticals (ANEB) reported a fiscal Q4 loss late Monday of $0.05 per diluted share, unchanged from a year earlier.
An analyst polled by FactSet expected $0.05 loss.
The company did not report any revenue for the quarter ended June 30.
As of June 30, the company said it had $11.6 million in cash and cash equivalents. It also has access to another $3 million in cash via a loan agreement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.